

ASX MEDIA RELEASE

18 February 2022

Upcoming release of shares subject to mandatory escrow arrangements

Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”) advises, in accordance with ASX Listing Rule 3.10A, that 65,796,554 fully paid ordinary shares subject to mandatory escrow arrangements at the time that Clarity was admitted to the official list of ASX, will be released from mandatory escrow on 25 February 2022.

Further details of the escrow arrangements were detailed in section 10.4 of Clarity’s Prospectus dated 16 July 2021 and section 2.2 of Clarity’s Supplementary Prospectus dated 18 August 2021.

This announcement has been authorised for release by the Executive Chairman of Clarity Pharmaceuticals.

For more information, please contact:

Dr Alan Taylor
Executive Chairman
ataylor@claritypharm.com

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com